AWSHX
Price
$67.56
Change
+$0.42 (+0.63%)
Updated
Jul 24 closing price
Net Assets
219.02B
HWLIX
Price
$48.98
Change
+$0.76 (+1.58%)
Updated
Jul 24 closing price
Net Assets
368.9M
Interact to see
Advertisement

AWSHX vs HWLIX

AWSHX vs HWLIX Comparison Chart in %
View a ticker or compare two or three
VS
AWSHX vs. HWLIX commentary
Jul 27, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AWSHX is a Buy and HWLIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
AWSHX has more cash in the bank: 219B vs. HWLIX (369M). HWLIX pays higher dividends than AWSHX: HWLIX (1.62) vs AWSHX (1.22). AWSHX was incepted earlier than HWLIX: AWSHX (74 years) vs HWLIX (39 years). HWLIX (0.98) is less costly to investors than AWSHX (0.55). HWLIX is a more actively managed with annual turnover of: 40.00 vs. AWSHX (29.00). AWSHX has a lower initial minimum investment than HWLIX: AWSHX (250) vs HWLIX (250000). HWLIX annual gain was more profitable for investors over the last year : 12.86 vs. AWSHX (5.14). AWSHX return over 5 years is better than : 26.98 vs. HWLIX (23.58).
AWSHXHWLIXAWSHX / HWLIX
Total Expense Ratio0.550.9558%
Annual Report Gross Expense Ratio0.550.9856%
Fund Existence74 years39 years-
Gain YTD4.2428.89348%
Front Load6%N/A-
Min. Initial Investment2502500000%
Min. Initial Investment IRAN/AN/A-
Net Assets219B369M59,350%
Annual Yield % from dividends1.221.6275%
Returns for 1 year5.1412.8640%
Returns for 3 years26.5118.78141%
Returns for 5 years26.9823.58114%
Returns for 10 years76.01115.3066%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STRC86.891.95
+2.29%
Strategy Inc Variable Rate Series A Perpetual Stretch Preferred Stock
MGM45.540.55
+1.22%
MGM Resorts International
DIN34.090.37
+1.10%
Dine Brands Global
MBINN19.95-0.06
-0.30%
Merchants Bancorp
IOVA4.99-0.14
-2.73%
Iovance Biotherapeutics